TGFB1 and neoplasm: proposed different liver TGF-β signatures in HCC cell lines and patients defining a cohort of genes related to its tumor suppressor capacities, which they designed as the “early signature” and another cohort of genes related to its tumor promoting effects, the “late signature” [31].